A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Ad26 Mos4 HIV (Primary) ; HIV clade C gp140 vaccine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Imbokodo
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 02 Jan 2018 Planned End Date changed from 3 Sep 2021 to 1 Feb 2022.
    • 30 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Johnson & Johnson media release.
    • 24 May 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top